ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "genomics"

  • Abstract Number: 0733 • ACR Convergence 2023

    Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening

    Guojun Hou1, Xinyi Zhu1, Yutong Zhang1, Zhaorui Cheng1 and Nan Shen2, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Genome-Wide Association Studies (GWAS) have unveiled over 1000 risk variants for lupus, predominantly situated in non-coding genomic regions. Their functional roles, especially their potential…
  • Abstract Number: 1785 • ACR Convergence 2023

    Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis

    Prakashini MV1, Soumendu Mahapatra2, Krushna Chandra Murmu2, Rasmita Mishra2, Prasanta Padhan1, Punit Prasad2, Ramnath Misra3 and Sakir Ahmed4, 1Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India, 2Institute of Life Sciences, Bhubaneswar, India, 3Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India, 4Kalinga Institute of Medical Sciences, Bhubaneswar, India

    Background/Purpose: Reactive arthritis (ReA) is the unique infection-triggered spondyloarthritis (SpA). Undifferentiated peripheral SpA (UpSpA) is similar but without previous infection, or psoriasis or inflammatory bowel…
  • Abstract Number: 0017 • ACR Convergence 2023

    Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity

    Diana Dou1, Yanding Zhao1, Julia Belk1, Yang Zhao1, Kerriann Casey2, Derek Chen1, Rui Li1, Bingfei Yu1, Suhas Srinivasan1, Brian Abe1, Katerina Kraft1, Ceke Hellström3, Ronald Sjöberg4, Sarah Chang5, Allan Feng5, Daniel Goldman6, Ami Shah7, Michelle Petri6, Lorinda Chung8, David Fiorentino9, Emma Lundberg10, Anton Wutz11, Paul Utz5 and Howard Chang1, 1Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Department of Dermatology, Stanford University School of Medicine, Stanford, CA, 2Department of Comparative Medicine, Stanford University, Stanford, CA, 3Autoimmunity and Serology Profiling, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, 4Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, 5Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 8Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 9Department of Dermatology, Stanford University School of Medicine, Menlo Park, CA, 10Departments of Bioengineering and Pathology, Stanford University, Stanford, CA, 11Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, ETH Hönggerberg, Zurich, Switzerland

    Background/Purpose: Autoimmune diseases disproportionately affect females more than males. The XX sex chromosome complement is strongly associated with susceptibility to autoimmunity. Xist long noncoding RNA…
  • Abstract Number: 0736 • ACR Convergence 2023

    Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics

    Juan Vargas1, Ian Mantel2, Nirmal Banda1, Anna Helena Jonsson3, Kevin Wei4, Deepak Rao3, Susan Goodman5, Kevin Deane1, The Accelerating Medicines Partnership SLE/RA1, Jennifer Anolik6, Michael Brenner4, Soumya Raychaudhuri3, Jennifer Seifert7, Michael Holer1, Laura Donlin5 and Fan Zhang8, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2Weill Cornell Medicine, New York, NY, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Hospital for Special Surgery, New York, NY, 6University of Rochester Medical Center, Rochester, NY, 7the Accelerating Medicines Partnership (AMP) RA/SLE Network, Boston, MA, 8University of Colorado, Aurora, CO

    Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in autoimmune disease pathogenesis. In patients with rheumatoid arthritis…
  • Abstract Number: 1833 • ACR Convergence 2023

    Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

    Jeffrey Rosenfeld1, Greta Linse2, Sally Slipher2, Candace Flint3, Annie Iserson3, Herbert Harris4, Jean Engels3, Gregory Sullivan5 and Seth Lederman6, 1Tonix Pharmaceuticals, Chatham, NJ, 2Montana State University, Bozeman, MT, 3Tonix Pharmaceuticals, New York, NY, 4Tonix Pharmaceuticals, Chapel Hill, NC, 5Tonix Pharmaceuticals Inc, Chatham, NJ, 6Tonix Pharmaceuticals, South Dartmouth, MA

    Background/Purpose: Fibromyalgia (FM) is characterized by widespread pain, non-restorative sleep, fatigue, and cognitive dysfunction. TNX-102 SL is a sublingual cyclobenzaprine tablet designed for daily use…
  • Abstract Number: 0018 • ACR Convergence 2023

    Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies

    Rayan Najjar1, Iago Pinal-Fernandez2, Andrew Mammen3 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2National Institutes of Health, Bethesda, MD, 3NIH, Bethesda, MD

    Background/Purpose: Alternative splicing of mRNA results in important biological impacts with increasing evidence implicating it in the pathology of autoimmune diseases. However, it is understudied…
  • Abstract Number: 0769 • ACR Convergence 2023

    Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort

    Austin Wheeler1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, K Wysham3, Grant Cannon4, Gary Kunkel5, Gail Kerr6, Dana Ascherman7, Paul Monach8, Andreas Reimold9, Jill Poole1, Tony Merriman10, Ted R Mikuls11 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7University of Pittsburgh, Pittsburgh, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Texas Southwestern Medical Center, Dallas, TX, 10University of Alabama at Birmingham, Birmingham, AL, 11Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
  • Abstract Number: 2105 • ACR Convergence 2023

    Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

    Hiroaki Tanaka1, Yukinori Okada2, Shingo Nakayamada1, Yusuke Miyazaki3, Kyuto Sonehara4, Shinichi Namba5, Suguru Honda6, Yuya Shirai7, Kenichi Yamamoto5, Katsunori Ikari8, Masayoshi Harigai9, KOSHIRO SONOMOTO10 and Yoshiya Tanaka1, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, 3The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, 4University of Tokyo, Tokyo, Japan, 5Osaka University, Osaka, Japan, 6Tokyo Women's Medical University, Tokyo, Japan, 7Osaka University, Suita, Japan, 8Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 9Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 10University of Occupational and Environmental Health, Beppu, Japan

    Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
  • Abstract Number: 0019 • ACR Convergence 2023

    Use of High-plex Data Reveals Novel Insights into the Temporal Artery Processus of Giant Cell Arteritis

    Simon Parreau1, Elsa Molina2, Stéphanie Dumonteil1, Radjiv Goulabchand3, Thomas Naves4, Melanie Bois5, Anne-Laure Fauchais1, Eric Liozon6, Marie-Odile Jauberteau4, Cornelia M. Weyand7 and Kim-Heang Ly1, 1Dupuytren Hospital, Limoges, France, 2Next Generation Sequencing Core, Salk Institute for Biological Studies, La Jolla, CA, 3University of California San Diego, La Jolla, CA, 4INSERM U1308, Limoges, France, 5Mayo Clinic, Rochester, MN, 6Department of Internal Medicine, University Hospital of Limoges, Limoges Cedex, Limoges, France, 7Mayo Clinic School of Medicine and Stanford University, Rochester, MN

    Background/Purpose: Uncover the key coding genes to define new biomarkers or pathways associated with GCA by performing the first in situ spatial profiling characterization of…
  • Abstract Number: 0873 • ACR Convergence 2023

    FOXO Activators as Drugs for Osteoarthritis

    Ichiro Kurakazu, Merissa Olmer, Kevin Myers and Martin K Lotz, Scripps Research Institute, La Jolla, CA

    Background/Purpose: Forkhead box O (FOXO) proteins are a family of transcription factors involved in lifespan, aging, and autophagy. FOXO are essential for maintaining cartilage homeostasis…
  • Abstract Number: 2331 • ACR Convergence 2023

    Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus

    Kevin Thomas1, Miles Smith1, Carla Guthridge1, Nicolas Dominguez1, Susan Macwana1, Wade DeJager1, Catriona Wagner1, Peter Schafer2, Stan Kamp1, Betty Diamond3, David Wofsy4, Aikaterini Thanou5, Cristina Arriens6, Cynthia Aranow3, Joan Merrill1, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Bristol Myers Squibb, Belle Mead, NJ, 3Feinstein Institutes for Medical Research, Manhasset, NY, 4University of California San Francisco, San Francisco, CA, 5University of Oklahoma Health, Edmond, OK, 6Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK

    Background/Purpose: Abatacept (ABA) is a fusion protein that disrupts T cell co-stimulation by inhibiting interactions between CD28 and CD80/86. ABA is effective in RA, but…
  • Abstract Number: 0022 • ACR Convergence 2023

    Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients

    Erika Hubbard1, Prathyusha Bachali2, Kathryn Kingsmore Allison1, Amrie Grammer1 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA

    Background/Purpose: We previously developed a novel machine learning (ML) pipeline leveraging analysis of gene expression data to identify subsets of SLE patients with common molecular…
  • Abstract Number: 0918 • ACR Convergence 2023

    Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus

    Katie Heitzman1, Sneha Dass1, Linda Hiraki2, Earl Silverman3, Christiaan Scott4, Ana Barrera-Vargas5, Zuoming Deng6, Mariana Kaplan7, Luis Franco8 and Laura Lewandowski9, 1Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Silverman, Toronto, ON, Canada, 4Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital and University of Cape Town, Cape Town, South Africa, 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 7Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 8Functional Immunogenomics Section, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, 9Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…
  • Abstract Number: 2345 • ACR Convergence 2023

    Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis

    Samir Parikh1, Salem Almaani2, Arnon Arazi3, Huijuan Song1, Pearlly Yan1, Estela Puchulu-Campanella1, Clint Abner4, Ernie Yap4, Krista Piper4, Robert B. Huizinga5 and Henry Leher4, 1Ohio State University, Columbus, OH, 2Ohio State University Medical Center, Columbus, OH, 3Broad Institute of MIT and Harvard, Melrose, MA, 4Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 5Reformation Consulting Services, North Saanich, BC, Canada

    Background/Purpose: Voclosporin is approved for the treatment of adults with active lupus nephritis. Addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids in the…
  • Abstract Number: 0026 • ACR Convergence 2023

    Mapping Cellular Landscape of Esophageal Epithelium in Systemic Sclerosis Using Single-cell Transcriptomics

    Matthew Dapas1, Hadijat Makinde2, Tyler Therron2, Margarette Clevenger2, Cenfu Wei2, Mary Karns3, Kathleen Aren3, Dustin Carlson2, Alexandra Soriano1, Lutfiyya Muhammad4, John Pandolfino5, Harris Perlman2, Deborah Winter6 and Marie-Pier Tetreault2, 1Northwestern University FSM Division of Rheumatology, Chicago, IL, 2Northwestern University, Chicago, IL, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Northwestern University, Feinberg School of Medicine, Wilmette, IL, 6Northwestern University, Skokie, IL

    Background/Purpose: Esophageal involvement is one of the strongest predictors of early mortality in individuals with systemic sclerosis (SSc). Individuals with SSc and esophageal involvement typically…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology